PERSPECTA

News from every angle

Back to headlines

Puma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programs

27 Feb, 02:38 — 27 Feb, 02:38
PostShare

Sources

Showing 1 of 1 sources